[Paid Post: @HKEX Group]
Investments in biotechnology have been rapidly gaining momentum in Hong Kong, particularly as the Covid-19 pandemic draws attention to new innovations in health care. In just three years, the city has become Asia’s largest biotech fundraising hub and the second-largest globally, thanks to listing reforms implemented by HKEX and proximity to the world’s second-largest health care industry in mainland China . Nicolas Aguzin, chief executive officer of HKEX, and Li Bin, founder and chief investment officer of health care-focused asset management firm Lake Bleu Capital, explain more about the factors behind Hong Kong’s vital role in the biotech growth story.

#Ad #HKEX #BiotechSummit #Biotech #HongKong

Full story: https://sc.mp/uwlb

Subscribe to our YouTube channel for free here: https://sc.mp/subscribe-youtube

Follow us on:
Website: https://scmp.com
SCMP Knowledge: https://www.scmp.com/knowledge
Facebook: https://facebook.com/scmp
Twitter: https://twitter.com/scmpnews
Instagram: https://instagram.com/scmpnews
Linkedin: https://www.linkedin.com/company/south-china-morning-post/